Neoleukin Therapeutics Analysis
Neoleukin Therapeutics is undervalued with Real Value of 0.0 and Hype Value of 0.0. The main objective of Neoleukin Therapeutics delisted stock analysis is to determine its intrinsic value, which is an estimate of what Neoleukin Therapeutics is worth, separate from its market price. There are two main types of Neoleukin Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Neoleukin Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Neoleukin Therapeutics is usually not traded on Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, National Mourning Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day. Neoleukin Stock trading window is adjusted to America/New York timezone.
Neoleukin |
Neoleukin Stock Analysis Notes
About 16.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.44. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Neoleukin Therapeutics recorded a loss per share of 12.28. The entity had not issued any dividends in recent years. The firm had 1:4 split on the 19th of December 2023. Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington. Neoleukin Therapeutics operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 79 people. To find out more about Neoleukin Therapeutics contact Jonathan MD at 855 226 6447 or learn more at https://www.neoleukin.com.Neoleukin Therapeutics Investment Alerts
| Neoleukin Therapeutics is not yet fully synchronised with the market data | |
| Neoleukin Therapeutics has some characteristics of a very speculative penny stock | |
| Neoleukin Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (57.56 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Neoleukin Therapeutics currently holds about 116.46 M in cash with (45.61 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.73. | |
| Roughly 16.0% of the company outstanding shares are owned by corporate insiders |
Neoleukin Therapeutics Upcoming and Recent Events
Earnings reports are used by Neoleukin Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
| 19th of March 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 19th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Neoleukin Market Capitalization
The company currently falls under 'Nano-Cap' category with a current market capitalization of 8.2 M.Neoleukin Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Neoleukin Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Neoleukin Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Neoleukin Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Todd Simpson over a year ago Acquisition by Todd Simpson of 25000 shares of Neoleukin Therapeutics subject to Rule 16b-3 | ||
Ventures West 8 Limited Partnership over a year ago Conversion by Ventures West 8 Limited Partnership of 1543989 shares of Neoleukin Therapeutics | ||
Todd Simpson over a year ago Acquisition by Todd Simpson of 25000 shares of Neoleukin Therapeutics subject to Rule 16b-3 | ||
Sean Smith over a year ago Exercise or conversion by Sean Smith of 12500 shares of Neoleukin Therapeutics subject to Rule 16b-3 |
Neoleukin Therapeutics Outstanding Bonds
Neoleukin Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Neoleukin Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Neoleukin bonds can be classified according to their maturity, which is the date when Neoleukin Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| TNEMAK 3625 28 JUN 31 Corp BondUS64045DAC83 | View | |
| US64049MAB63 Corp BondUS64049MAB63 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Neoleukin Therapeutics to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Money Managers Now
Money ManagersScreen money managers from public funds and ETFs managed around the world |
| All Next | Launch Module |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Other Consideration for investing in Neoleukin Stock
If you are still planning to invest in Neoleukin Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Neoleukin Therapeutics' history and understand the potential risks before investing.
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |